| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| M4 |
|
C52H89N15O18S2 |
1276.48 |
H2N–DPCGERICSIAL–OH |
H2N–Asp–Pro–Cys–Gly–Glu–Arg–Ile–Cys–Ser–Ile–Ala–Leu–OH |
12 |
MPXV B21R protein–targeting peptide |
|
| M6 |
|
C52H87N13O17S2 |
1230.45 |
H2N–SCSSFLCSLKVG–OH |
H2N–Ser–Cys–Ser–Ser–Phe–Leu–Cys–Ser–Leu–Lys–Val–Gly–OH |
12 |
MPXV B21R protein–targeting peptide |
|
| Ac-DMLD-CMK |
2588354-33-8 |
C22H35O9N4S1Cl1 |
567.05 |
Ac–DMLD–CMK |
Ac–Asp–Met–Leu–Asp–CMK |
4 |
Mouse caspase-3–GSDME signaling pathway–targeting peptide |
|
| XRB2 |
|
C31H57N7O11S2 |
767.95 |
H2N–MSMSSIL–OH |
H2N–Met–Ser–Met–Ser–Ser–Ile–Leu–OH |
7 |
Red blood cell exosome–targeting peptide |
|
| XRE4 |
|
C42H53N7O11 |
831.91 |
H2N–FASPFYT–OH |
H2N–Phe–Ala–Ser–Pro–Phe–Tyr–Thr–OH |
7 |
Red blood cell exosome–targeting peptide |
|
| XRH7 |
|
C64H91N17O17 |
1370.51 |
H2N–FQVTGPLTQWGH–OH |
H2N–Phe–Gln–Val–Thr–Gly–Pro–Leu–Thr–Gln–Trp–Gly–His–OH |
12 |
Red blood cell exosome–targeting peptide |
|
| M5.2 |
|
C41H63N9O12S2 |
938.12 |
H2N–CGPIYTALC–OH |
H2N–Cys–Gly–Pro–Ile–Tyr–Thr–Ala–Leu–Cys–OH |
9 |
MUC5AC-targeting peptide |
|
| M2.3 |
|
C36H59N15O14S2 |
990.08 |
H2N–CDGRPDRAC–OH |
H2N–Cys–Asp–Gly–Arg–Pro–Asp–Arg–Ala–Cys–OH |
9 |
MUC2-targeting peptide |
|
| BMP-4 acetate |
|
C52H93N25O13S1 |
1308.52 |
H2N–RKKNPNCRRH–OH |
H2N–Arg–Lys–Lys–Asn–Pro–Asn–Cys–Arg–Arg–His–OH |
10 |
Cell-penetrating heparin-binding peptide |
|
| T37 |
|
C39H57N13O9 |
851.95 |
H2N–GWHSIPR–OH |
H2N–Gly–Trp–His–Ser–Ile–Pro–Arg–OH |
7 |
CLDN18.2-targeting peptide |
|
| DAP1-2 |
|
C122H183N37O40 |
2807.98 |
H2N–ADPQNRLELNQYNQWRDEQYVK–OH |
H2N–Ala–Asp–Pro–Gln–Asn–Arg–Leu–Glu–Leu–Asn–Gln–Tyr–Asn–Gln–Trp–Arg–Asp–Glu–Gln–Tyr–Val–Lys–OH |
22 |
IL-1R1 receptor–targeting peptide |
|
| ANP [Des18-22] 4-23 amide rat |
|
C64H107N25O19S2 |
1594.82 |
H2N–RSSCFGGRIDRIGAC–NH2 |
H2N–Arg–Ser–Ser–Cys–Phe–Gly–Gly–Arg–Ile–Asp–Arg–Ile–Gly–Ala–Cys–NH2 |
15 |
|
|
| RRQPPRSISSHP |
|
C59H100N24O17 |
1417.58 |
H2N–RRQPPRSISSHP–OH |
H2N–Arg–Arg–Gln–Pro–Pro–Arg–Ser–Ile–Ser–Ser–His–Pro–OH |
12 |
Skeletal muscle–targeting peptide |
|
| TMTP1 |
|
C25H46N10O8 |
614.69 |
H2N–NVVRQ–OH |
H2N–Asn–Val–Val–Arg–Gln–OH |
5 |
Hematologic malignancies and metastatic lesion–targeting peptide |
|
| CSP3 |
|
C55H86N14O22 |
1295.35 |
H2N–QQLPSSSTSTYP–OH |
H2N–Gln–Gln–Leu–Pro–Ser–Ser–Ser–Thr–Ser–Thr–Tyr–Pro–OH |
12 |
Cervical cancer cell–targeting peptide |
|
| BB1 |
|
C31H49N11O16S2 |
895.91 |
H2N–CVGNDNSSC–OH |
H2N–Cys–Val–Gly–Asn–Asp–Asn–Ser–Ser–Cys–OH |
9 |
Human kidney–derived TEC–targeting peptide |
|
| RWY |
|
C48H64N14O16S2 |
1157.24 |
H2N–CRWYDENAC–OH |
H2N–Cys–Arg–Trp–Tyr–Asp–Glu–Asn–Ala–Cys–OH |
9 |
Integrin α6–targeting peptide |
|
| 3BP-4089TFA |
|
C53H74F3N9O13S3 |
1198.4 |
Hex–[K(tMeBn(H-AET))–PPTQFC]–OH |
Hex–[Cys(tMeBn(H-AET))–Pro–Pro–Thr–Gln–Phe–Cys]–OH |
7 |
FAP–targeting peptide |
|
| G3-C12 |
|
C74H115N23O23S2 |
1758.98 |
H2N–ANTPCGPYTHDCPVKR–OH |
H2N–Ala–Asn–Thr–Pro–Cys–Gly–Pro–Tyr–Thr–His–Asp–Cys–Pro–Val–Lys–Arg–OH |
16 |
Galectin-3 receptor–targeting peptide |
|
| D8 |
|
C43H70N18O12 |
1031.13 |
H2N–rTGrarEw–OH |
H2N–DArg–Thr–Gly–DArg–DAla–DArg–Glu–DTrp–OH |
8 |
Brain-targeting peptide |
|
